Description
Venteze Inhaler is indicated for relief of bronchospasm in bronchial asthma of all types, chronic bronchitis and emphysema and has been found to be suitable for the relief of bronchospasm in patients with co-existing heart disease, although caution is advised.
Salbutamol is a beta-adrenergic stimulant which has a highly selective action on the receptors in bronchial muscle and, in therapeutic dosage, little or no action on the cardiac receptors. The inhaler drug delivery system, using Salbutamol in microgram dosage, avoids the skeletal muscle tremor sometimes associated with oral therapy.
Published clinical evidence indicates that the action of Salbutamol by inhalation is rapid, near maximal bronchodilation occurring within five minutes. Venteze Inhaler in therapeutic dosages has minimal effect on the cardiovascular system. It has been found that Venteze has no significant effect on the heart rate and circulation time and it does not lead to a significant fall in lowered arterial oxygen tension.
- Always refer to the enclosed leaflet before use.
- Shake before use. Do not exceed the recommended dose.
- One or two inhalations repeated 4 hourly if required.
- The bronchodilator effect of each administration of Venteze Inhaler lasts for at least 4 hours and more frequent use should be unnecessary. This long duration of action provides a margin of safety.
- The patient can readily recognise any reduction in the length of action and should be instructed to consult a doctor if the effect of a previously adequate dose lasts for less than 3 hours.
- Venteze Inhaler acts rapidly and may be used when necessary to relieve attacks of acute dyspnoea. Doses may be taken prophylactically before exertion or to prevent exercise-induced asthma.
- Because the bronchodilator effect of each administration is long-acting, it is ideally suited for routine maintenance therapy in chronic asthma and chronic bronchitis when a degree of reversible airways obstruction exists.